查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1279849

2023-2030年全球急性髓性白血病市場規模研究與預測，按化療方法（阿糖胞苷、蒽環類藥物、烷化劑、抗代謝藥、酪氨酸激酶抑製劑、激素療法、其他化療方法）和區域分析

Global Acute Myeloid Leukemia Market Size Study & Forecast, By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy, Other Chemotherapies), and Regional Analysis, 2023-2030
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

急性骨髓性白血病（AML）是一种血癌和骨髓中不成熟白細胞過多的形式。它的特點是不成熟的骨髓細胞迅速增殖，這是一種負責對抗感染的白血球。這些不成熟的細胞在急性髓系白血病患者的骨髓中聚集，阻礙健康血細胞的形成，從而導致症狀和問題。急性骨髓性白血病發病率的增加，新型療法的不斷推出，對精準醫療的重視，免疫療法的採用激增，以及醫療開支的增加，是促進全球市場需求的主要因素。

此外，老年人口的增加也是全球市場增長的一個催化因素。根據美國癌症協會的數據，急性髓細胞白血病通常發生在老年人群中，45歲之前並不常見。此外，AML的平均年齡接近68歲。世界衛生組織（WHO）報告說，預計老齡人口的數量將從2020年的10億增加到2030年的15億，全世界60歲以上的人中佔1/6。因此，快速增長的老年人口更容易受到急性骨髓性白血病的影響，這為市場增長創造了有利可圖的機會。此外，藥理學和分子生物學的不斷進步促進了藥物開發，以及對研究和開發的投資不斷增加，在預測的幾年裡呈現各種有利可圖的機會。例如2022年5月，FDA 宣布他們批准 Tibsovo、Servier Pharmaceuticals LLC 的 ivosidenib 與阿扎胞苷（注射用阿扎胞苷）的混合物用於新診斷的急性髓性白血病 (AML)。 此外，它涉及一種易感的IDH1突變，該突變通過FDA批准的測試在75歲及以上的成年人或患有妨礙強化誘導化療的合併症的成年人中測試。 然而，在整個 2023-2030 年的預測期內，對化療相關藥物和並發症的嚴格監管限制了市場增長。

全球急性髓性白血病市場研究涵蓋的主要地區包括亞太、北美、歐洲、拉丁美洲、中東和非洲。由於急性骨髓性白血病病例的發病率不斷增加，技術進步不斷提高，以及越來越重視以病人為中心的方法，北美在2022年主導了市場。美國癌症協會表示，在2023年，大約有59,610個白血病新病例和23,710個白血病死亡病例。而在預測期內，亞太地區預計將以最高的年復合增長率增長，原因是政府的有利計劃、開展的臨床試驗數量不斷增加、醫療保健支出不斷增加以及分子診斷技術的不斷進步等因素。

該研究的目的是定義近年來不同市場區隔和國家的市場規模，並預測未來幾年的價值。該報告旨在涵蓋參與研究的國家/地區的該行業的定性和定量方面。

該報告還提供了關於關鍵方面的詳細資訊，如驅動因素和挑戰，這將確定市場的未來增長。此外，它還涵蓋了微觀市場的潛在機會，供利益相關者投資，並詳細分析了競爭格局和主要參與者的產品。 .

目錄

第一章：執行摘要

  • 市場簡介
  • 2020-2030年全球和細分市場的估計和預測
    • 2020-2030年急性髓性白血病市場，按地區分類
    • 2020-2030年，急性髓系白血病市場，按化療方法分類
  • 主要趨勢
  • 估算方法
  • 研究假設

第二章：全球急性骨髓性白血病市場的定義和範圍

  • 本研究的目的
  • 市場定義和範圍
    • 行業演變
    • 研究的範圍
  • 研究涵蓋的年份
  • 貨幣轉換率

第三章：全球急性髓系白血病市場動態

  • 急性骨髓性白血病市場影響分析（2020-2030）。
    • 市場驅動力
      • 急性骨髓性白血病的發病率越來越高
      • 老年人口不斷增加
    • 市場挑戰
      • 嚴格的藥物規定
      • 與化療相關的並發症
    • 市場機會
      • 藥理學和分子生物學的不斷進步，促進藥物開發
      • 增加研究和開發的投資

第四章：全球急性髓系白血病市場行業分析

  • 波特五力模型
    • 供應商的議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭性的競爭
  • 波特五力影響分析
  • PEST分析
    • 政治
    • 經濟
    • 社會
    • 技術
    • 環境
    • 法律問題
  • 最佳投資機會
  • 最佳策略
  • COVID-19影響分析
  • 顛覆性趨勢
  • 行業專家的觀點
  • 分析師建議與結論

第五章：全球急性髓系白血病市場，按化療方法分類

  • 市場簡介
  • 全球急性髓性白血病市場，按化療方法，表現- 潛力分析
  • 2020-2030年全球急性骨髓性白血病市場按化療方法的估計和預測
  • 急性骨髓性白血病市場，分項分析
    • 阿糖胞苷
    • 蒽環類藥物
    • 烷基化藥物
    • 抗代謝藥
    • 酪氨酸激酶抑製劑
    • 激素治療
    • 其他化療藥物

第六章：全球急性髓系白血病市場，區域分析

  • 最領先的國家
  • 新興國家
  • 急性骨髓性白血病市場，區域市場簡介
  • 北美洲
    • 美國
      • 2020-2030年化療分類估計和預測
    • 加拿大
  • 歐洲急性髓系白血病市場簡介
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區急性髓系白血病市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 亞太其他地區
  • 拉丁美洲急性骨髓性白血病市場簡介
    • 巴西
    • 墨西哥
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 中東和非洲其他地區

第七章：競爭情報

  • 主要公司SWOT分析
    • 公司1
    • 公司二
    • 公司3
  • 頂級市場戰略
  • 公司簡介
    • Novartis AG
      • 關鍵資訊
      • 概況
      • 財務（取決於數據的可用性）
      • 產品摘要
      • 近期發展情況
    • Genmab AS
    • Otsuka Holdings Co. Ltd
    • Sanofi-Aventis (Genzyme Corporation)
    • Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Sunesis Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • Oncolyze Inc.

第八章：研究過程

  • 研究過程
    • 資料探勘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 研究屬性
  • 研究假設

Global Acute Myeloid Leukemia Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Acute Myeloid Leukemia (AML) is a form of blood cancer and bone marrow with excess immature white blood cells. It is characterized by the rapid proliferation of immature myeloid cells, which are a type of white blood cell responsible for fighting infections. These immature cells amass in the bone marrow in AML and obstruct the formation of healthy blood cells, resulting in symptoms and problems. The increasing prevalence of acute myeloid leukemia, the rising introduction of novel therapies, the rising emphasis on precision medicine, the surging adoption of immunotherapies, and increasing healthcare expenditure are the primary factors that are attributing to the market demand across the globe.

In addition, the rising geriatric population is acting as a catalyzing factor for market growth across the globe. According to the American Cancer Society, AML is usually occurred among the older population and is uncommon before the age of 45. Also, the average age for AML is nearly 68. The World Health Organization (WHO) reported that it is anticipated that the number of aging people increase from 1 billion in 2020 to 1.5 billion in 2030 which worldwide accounts for 1 in 6 people above 60. Hence, the rapidly growing geriatric population is more prone to be affected by acute myeloid leukemia, which is creating lucrative opportunities for market growth. Moreover, rising advancements in pharmacology and molecular biology to promote drug development, as well as the increasing investments in research and development are presenting various lucrative opportunities over the forecasting years. For instance, in May 2022, the FDA declared that they approved Tibsovo, Servier Pharmaceuticals LLC's ivosidenib in a mixture with azacitidine (azacitidine for injection) for novel diagnosed acute myeloid leukemia (AML). Additionally, it involves a susceptible IDH1 mutation identified by an FDA-approved test in adults aged 75 years and over or with comorbidities that prevent intensive induction chemotherapy. However, the stringent regulations on drugs and complications related to chemotherapy are restricting the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Acute Myeloid Leukemia Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing incidences of acute myeloid leukemia cases, rising technological advancements, and growing focus on patient-centric approaches. The American Cancer Society stated that in 2023, approximately 59,610 new cases of leukemia and 23,710 deaths from leukemia were recorded. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as favorable government initiatives, an increasing number of clinical trials conducted, rising healthcare expenditure, and growing advancements in molecular diagnostics.

Major market players included in this report are:

  • Novartis AG
  • Genmab AS
  • Otsuka Holdings Co. Ltd
  • Sanofi-Aventis (Genzyme Corporation)
  • Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sunesis Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Oncolyze Inc.

Recent Developments in the Market:

  • In January 2022, Oncolyze announced that OM-301, a medication used to treat acute myeloid leukaemia (AML), had been granted FDA orphan drug designation.
  • In December 2021, SNDX-5613, a highly specific oral menin inhibitor for the treatment of acute myeloid leukaemia (AML), was approved as an orphan drug by the European Commission.

Global Acute Myeloid Leukemia Market Report Scope:

  • Historical Data: - 2020 - 2021
  • Base Year for Estimation: - 2022
  • Forecast period: - 2023-2030
  • Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: - Chemotherapy, Region
  • Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Chemotherapy:

  • Cytarabine
  • Anthracycline Drugs
  • Alkylating Agents
  • Anti-metabolites
  • Tyrosine Kinase Inhibitors
  • Hormonal Therapy
  • Other Chemotherapies

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Acute Myeloid Leukemia Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Acute Myeloid Leukemia Market, by Chemotherapy, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Acute Myeloid Leukemia Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Acute Myeloid Leukemia Market Dynamics

  • 3.1. Acute Myeloid Leukemia Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of acute myeloid leukemia
      • 3.1.1.2. Rising geriatric population
    • 3.1.2. Market Challenges
      • 3.1.2.1. Stringent regulations on drugs
      • 3.1.2.2. Complications related to chemotherapy
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising advancements in pharmacology and molecular biology to promote drug development
      • 3.1.3.2. Increasing investments in research and development

Chapter 4. Global Acute Myeloid Leukemia Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Acute Myeloid Leukemia Market, by Chemotherapy

  • 5.1. Market Snapshot
  • 5.2. Global Acute Myeloid Leukemia Market by Chemotherapy, Performance - Potential Analysis
  • 5.3. Global Acute Myeloid Leukemia Market Estimates & Forecasts by Chemotherapy 2020-2030 (USD Billion)
  • 5.4. Acute Myeloid Leukemia Market, Sub Segment Analysis
    • 5.4.1. Cytarabine
    • 5.4.2. Anthracycline Drugs
    • 5.4.3. Alkylating Agents
    • 5.4.4. Anti-metabolites
    • 5.4.5. Tyrosine Kinase Inhibitors
    • 5.4.6. Hormonal Therapy
    • 5.4.7. Other Chemotherapies

Chapter 6. Global Acute Myeloid Leukemia Market, Regional Analysis

  • 6.1. Top Leading Countries
  • 6.2. Top Emerging Countries
  • 6.3. Acute Myeloid Leukemia Market, Regional Market Snapshot
  • 6.4. North America Acute Myeloid Leukemia Market
    • 6.4.1. U.S. Acute Myeloid Leukemia Market
      • 6.4.1.1. Chemotherapy breakdown estimates & forecasts, 2020-2030
    • 6.4.2. Canada Acute Myeloid Leukemia Market
  • 6.5. Europe Acute Myeloid Leukemia Market Snapshot
    • 6.5.1. U.K. Acute Myeloid Leukemia Market
    • 6.5.2. Germany Acute Myeloid Leukemia Market
    • 6.5.3. France Acute Myeloid Leukemia Market
    • 6.5.4. Spain Acute Myeloid Leukemia Market
    • 6.5.5. Italy Acute Myeloid Leukemia Market
    • 6.5.6. Rest of Europe Acute Myeloid Leukemia Market
  • 6.6. Asia-Pacific Acute Myeloid Leukemia Market Snapshot
    • 6.6.1. China Acute Myeloid Leukemia Market
    • 6.6.2. India Acute Myeloid Leukemia Market
    • 6.6.3. Japan Acute Myeloid Leukemia Market
    • 6.6.4. Australia Acute Myeloid Leukemia Market
    • 6.6.5. South Korea Acute Myeloid Leukemia Market
    • 6.6.6. Rest of Asia Pacific Acute Myeloid Leukemia Market
  • 6.7. Latin America Acute Myeloid Leukemia Market Snapshot
    • 6.7.1. Brazil Acute Myeloid Leukemia Market
    • 6.7.2. Mexico Acute Myeloid Leukemia Market
  • 6.8. Middle East & Africa Acute Myeloid Leukemia Market
    • 6.8.1. Saudi Arabia Acute Myeloid Leukemia Market
    • 6.8.2. South Africa Acute Myeloid Leukemia Market
    • 6.8.3. Rest of Middle East & Africa Acute Myeloid Leukemia Market

Chapter 7. Competitive Intelligence

  • 7.1. Key Company SWOT Analysis
    • 7.1.1. Company 1
    • 7.1.2. Company 2
    • 7.1.3. Company 3
  • 7.2. Top Market Strategies
  • 7.3. Company Profiles
    • 7.3.1. Novartis AG
      • 7.3.1.1. Key Information
      • 7.3.1.2. Overview
      • 7.3.1.3. Financial (Subject to Data Availability)
      • 7.3.1.4. Product Summary
      • 7.3.1.5. Recent Developments
    • 7.3.2. Genmab AS
    • 7.3.3. Otsuka Holdings Co. Ltd
    • 7.3.4. Sanofi-Aventis (Genzyme Corporation)
    • 7.3.5. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
    • 7.3.6. Pfizer Inc.
    • 7.3.7. F. Hoffmann-La Roche Ltd
    • 7.3.8. Sunesis Pharmaceuticals Inc.
    • 7.3.9. Astellas Pharma Inc.
    • 7.3.10. Oncolyze Inc.

Chapter 8. Research Process

  • 8.1. Research Process
    • 8.1.1. Data Mining
    • 8.1.2. Analysis
    • 8.1.3. Market Estimation
    • 8.1.4. Validation
    • 8.1.5. Publishing
  • 8.2. Research Attributes
  • 8.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Acute Myeloid Leukemia Market, report scope
  • TABLE 2. Global Acute Myeloid Leukemia Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Acute Myeloid Leukemia Market estimates & forecasts by Chemotherapy 2020-2030 (USD Billion)
  • TABLE 4. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 5. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. U.S. Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 16. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. Canada Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. UK Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 21. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. Germany Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 24. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. France Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 27. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. Italy Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 30. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Spain Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 33. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. RoE Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 36. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. China Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 39. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. India Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 42. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. Japan Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 45. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. South Korea Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 48. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. Australia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 51. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. Brazil Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 57. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Mexico Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 60. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. RoLA Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 63. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. Saudi Arabia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 66. South Africa Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoMEA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Acute Myeloid Leukemia Market
  • TABLE 69. List of primary sources, used in the study of global Acute Myeloid Leukemia Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Acute Myeloid Leukemia Market, research methodology
  • FIG 2. Global Acute Myeloid Leukemia Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Acute Myeloid Leukemia Market, key trends 2022
  • FIG 5. Global Acute Myeloid Leukemia Market, growth prospects 2023-2030
  • FIG 6. Global Acute Myeloid Leukemia Market, porters 5 force model
  • FIG 7. Global Acute Myeloid Leukemia Market, pest analysis
  • FIG 8. Global Acute Myeloid Leukemia Market, value chain analysis
  • FIG 9. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Acute Myeloid Leukemia Market, regional snapshot 2020 & 2030
  • FIG 15. North America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable